Treatment of Angiolipoma (Skin Angioma)
For angiolipomas of the skin, surgical excision is the definitive treatment of choice, with selective arterial embolization recommended for larger lesions at risk of bleeding.
Understanding Angiolipomas
Angiolipomas are benign subcutaneous tumors characterized by:
- Typically located in subcutaneous tissues, with over 51% in the upper extremity 1
- Median size of 2.4 cm (range 0.4-7.7 cm) 1
- Lobulated bean shape that abuts the skin 1
- Contain both adipose tissue and vascular elements 1
Treatment Algorithm
1. Small, Asymptomatic Angiolipomas (<4 cm)
- Active surveillance with yearly ultrasound imaging 2
- No immediate intervention required unless symptomatic
- MRI is preferred for ongoing surveillance when ultrasound is technically unreliable 2
2. Symptomatic or Large Angiolipomas (>4 cm)
- Surgical excision is the primary treatment for symptomatic lesions 2
- Complete surgical removal provides definitive treatment and histological diagnosis 1
- Nephron-sparing surgical approach is strongly recommended when treating renal angiolipomas 3
3. Angiolipomas with High Bleeding Risk
- Selective arterial embolization is the first-line approach for lesions with:
- Steroid prophylaxis is strongly recommended to prevent post-embolization syndrome 3, 2
4. Medical Management Option
- mTORC1 inhibitors (everolimus) can be considered for:
- Continue treatment for minimum 12 months before assessing response 3
- Temporary discontinuation during severe infection or adverse effects 3
Special Considerations
For Renal Angiolipomas
For Cutaneous Angiolipomas
- Surgical excision is typically curative 1
- For multiple lesions, consider:
Follow-up and Monitoring
- Post-treatment imaging to confirm successful treatment 2
- Regular imaging surveillance based on tumor size and risk factors 2
- MRI is preferred for ongoing surveillance 2
- Follow-up intervals of 1-3 years for smaller lesions 2
Potential Complications
- Post-embolization syndrome (manageable with prophylactic steroids) 3, 2
- Surgical complications including bleeding (5.4%) and need for blood transfusion (up to 9.1%) 2
- Side effects of mTORC1 inhibitors include stomatitis, irregular menstruation, hyperlipidemia, and dermatitis 3